BioWorld

March 8, 2002

Celgene Changing Course On Thalomid In Multiple Myeloma

Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today) Read More

Cubist Plans Cidecin NDA Filing This Year For Treating Infections

Besides Biting Fly, Parasitical Worm, River Blindness Needs Wolbachia Bacterial Infectivity

PDUFA Negotiations Likely To Lead To Increased Filing Fees

Other News To Note

Medicines Company Licenses Phase III Drug From AstraZeneca

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Medline raises $6.3B in fourth med-tech IPO of December

BioWorld MedTech

Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Acryl raises $28M IPO, aiming to bridge medical divide with AI

BioWorld MedTech

Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...